Skip to Main Content

Paper Details

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.
Cancer Discov
183
2019
DLBCL, EZH2, EZH2 mutations, EZH2-mutated human DLBCL cell lines, GC, GC-derived lymphomas, MHC, MHC Deficiency, MHC deficiency, MHC-I, MHC-I- and MHC-II-negative primary lymphomas, MHC-II, MHC-II-deficient tumors, MHC-deficient lymphoid tumors, T-cell infiltrates, centroblast, deficiency of MHC expression, diffuse large B-cell lymphoma, human, lymphoma, murine lymphoma models, mutant Ezh2, patients, tumor, tumor-infiltrating lymphocytes, tumors

Datasets

Release 1.2